Biography of Agragesh Ramani: Co-Founder and CEO of Trunome & AcrannoLife- Entrepreneur
Biography of Agragesh Ramani:
Agragesh Ramani is an entrepreneur who has demonstrated
remarkable versatility in his career, successfully launching and leading
multiple startups in diverse sectors. Currently, he serves as the Co-Founder
and CEO of AcrannoLife Genomics, a healthcare technology company focused on
chronic disease management. Additionally, he is the co-founder of Trunome, a
cutting-edge startup aimed at revolutionizing how chronic diseases are
diagnosed and monitored.
Educational Background: A Blend of Engineering and Business
Agragesh’s academic journey began with an engineering degree
in Electronics and Instrumentation from Anna University in Chennai. This
technical foundation laid the groundwork for his future entrepreneurial
ventures, where he combined his engineering knowledge with business management
expertise. Later, he pursued an MBA in Marketing Management and Finance from
the Institute of Management Technology, Ghaziabad (IMT Ghaziabad), where he
gained invaluable skills in leadership, marketing, and finance.
Early Career and Startup Experiences
Agragesh’s career path has been defined by a variety of
roles, primarily in startup environments where he could leverage his diverse
skill set. His early experience with startups gave him a broad understanding of
what it takes to run a business, especially in areas such as Sales, Brand
Marketing, Digital Marketing, Business Intelligence (BI), and Financial
Planning & Analysis (FP&A). Working with companies like Zovi, Little
App, and Paytm, he gained firsthand experience in sales, customer acquisition,
and handling profit-and-loss responsibilities.
The Birth of AcrannoLife Genomics
In February 2019, Agragesh co-founded AcrannoLife Genomics,
a clinical genomics company focused on improving healthcare for chronic disease
patients. The idea behind AcrannoLife was born from personal experiences within
his family, where loved ones had suffered from chronic ailments. The company's
mission is to create affordable, personalized healthcare solutions using
genomics technology to improve the lives of chronic patients. AcrannoLife holds
several international patents (PCT & US) for its innovative healthcare
products and continues to expand its tech offerings.
Award-Winning Journey in Healthcare Innovation
Agragesh’s work with AcrannoLife has earned him numerous
accolades. The company won prestigious awards such as ET-Power of Ideas and was
recognized as one of the top healthcare startups in India at the NATHEALTH
Annual Event. AcrannoLife’s innovations have been presented at international
medical forums, and the company has also been honored by the President of India
for its outstanding contributions to healthcare innovation.
Shark Tank India: A Major Milestone
One of the most significant moments in Agragesh’s
entrepreneurial journey came when Trunome, another one of his startups,
appeared on Shark Tank India Season 2. On the show, Agragesh and his team
pitched their groundbreaking technology for the early diagnosis and monitoring
of chronic diseases. Their innovative approach, which included blood tests for
detecting diseases like cancer recurrence, impressed the sharks. Ultimately,
they secured a deal with investors Anupam Mittal, Vineeta Singh, Aman Gupta, and
Peyush Bansal, who invested ₹1.5 crores for 2% equity in the company.
Building a Patient-Centric Healthcare Model
Agragesh’s vision for healthcare has always been deeply
patient-centric. With AcrannoLife Genomics, the focus is on building technology
that empowers patients with chronic conditions, providing them with innovative
solutions to manage their health. By leveraging genomics and personalized
medicine, AcrannoLife is making it possible for patients to make informed
decisions about their health and improve their quality of life.
Technological Innovation: Trunome’s Patented Platform
Trunome, the healthcare startup Agragesh co-founded with his
brother Avinash Ramani, has developed a patented platform for early diagnosis
and continuous monitoring of chronic diseases. Their solution is designed to
identify diseases such as cancer recurrence at the earliest possible stage
through simple blood tests. This breakthrough has the potential to change the
way chronic diseases are diagnosed, allowing for earlier interventions and
better treatment outcomes.
Impacting Lives: Trunome’s Reach and Growth
Since its inception, Trunome has impacted the lives of over
1500 patients, having tested over 5000 samples. The startup has partnered with
leading hospitals across India, which helps them to expand their reach and
bring their life-saving technology to more patients. Agragesh’s long-term
vision is to positively impact over one billion people worldwide, improving
both their physical and emotional well-being through accessible, early-stage
diagnosis and monitoring.
Biography of Agragesh Ramani: Co-Founder and CEO of Trunome & AcrannoLife/ age/net worth/investor/startup/entrepreneur/chronic disease management
Target Market: Chronic Disease Patients and Organ Transplant
Recipients
Trunome’s primary target market consists of patients
suffering from chronic diseases, particularly organ transplant recipients.
Monitoring these patients post-transplant is not only expensive but also
extremely challenging. Trunome’s solution provides a much-needed tool for these
patients, enabling doctors to track their health more accurately and provide
timely interventions when needed. This offers both patients and healthcare
providers a cost-effective, reliable alternative to traditional methods.
Business Model: B2B Approach with Healthcare Providers
Trunome operates primarily through a B2B
(business-to-business) model, partnering with hospitals and healthcare
providers to offer their diagnostic services. This collaboration ensures that
Trunome’s technology can reach the patients who need it most. The company
generates revenue by charging fees for its diagnostic services and continues to
expand its hospital network, which will allow it to serve an even larger
patient base as it grows.
Funding and Investor Support: The Shark Tank Deal
The funding secured on Shark Tank India was a pivotal moment
for Trunome. The startup was looking to raise ₹1.5 crores for 1% equity,
valuing the company at ₹150 crore. After intense negotiations, Trunome settled
on ₹1.5 crores for 2% equity, bringing down the valuation to ₹75 crore. This
deal provided not only the necessary capital but also the credibility and
support of four prominent investors—Peyush Bansal, Anupam Mittal, Vineeta
Singh, and Aman Gupta—who believe in Trunome’s potential to make a global impact.
A Growing Network: Partnerships with Leading Hospitals
Trunome’s technology has already been integrated into the
workflows of six major hospitals in India, positioning the startup to expand
its presence in the healthcare ecosystem. These partnerships help the company
scale its impact, offering a new, more accurate way of diagnosing chronic
diseases to a large and growing population. The company’s long-term goal is to
reach and positively impact the lives of millions through its network of
healthcare partnerships.
Trunome’s Global Impact and Future Vision
Agragesh and Avinash have ambitious plans for Trunome’s
global expansion. The technology’s ability to diagnose chronic diseases with
100% accuracy through blood tests is a game-changer for the healthcare
industry. With continued development and more partnerships with hospitals
globally, Trunome is on track to help millions of people worldwide improve
their health and quality of life, especially those struggling with chronic
diseases like cancer and organ transplant complications
From Idea to Reality: Agragesh’s Entrepreneurial Journey
Agragesh Ramani’s journey from an engineering student to a
successful healthcare entrepreneur reflects his commitment to leveraging
technology to solve real-world problems. From his early experiences in startup
environments to co-founding AcrannoLife and Trunome, Agragesh’s entrepreneurial
vision has always been clear: use innovation to improve healthcare and change
the lives of patients for the better.
The Role of Family and Personal Experience in Shaping the
Vision
Agragesh's motivation for starting AcrannoLife and Trunome
is deeply personal. His family’s experiences with chronic diseases inspired him
to seek technological solutions that could make a real difference in people’s
lives. This personal connection to the mission has fueled his passion and
determination to build companies that not only succeed in the market but also
have a positive social impact
Looking Ahead: The Future of Trunome and AcrannoLife
With the funding secured and the increasing demand for
better healthcare solutions, Agragesh is focused on scaling Trunome and
AcrannoLife to new heights. He believes that the future of healthcare lies in
personalized medicine and genomic testing, and his companies are at the
forefront of this revolution. As both startups continue to grow, Agragesh’s
vision of making healthcare more accessible, affordable, and effective will
continue to shape the future of the industry.
A timeline based on Agragesh Ramani's journey:
2008-2012 - Agragesh completes Engineering (Electronics and
Instrumentation) at Anna University, Chennai.
2012-2014 - Pursues an MBA in Marketing and Finance at IMT
Ghaziabad.
2014-2017 - Works at Zovi, Little App, and Paytm, gaining
startup experience in Sales, Marketing, and Business Intelligence.
February 2019 - Co-founds AcrannoLife Genomics, focusing on
chronic disease management through genomics.
2020 - AcrannoLife wins awards like ET-Power of Ideas and
recognition at NATHEALTH.
2021 - Agragesh and team pitch Trunome on Shark Tank India;
secure ₹1.5 crores for 2% equity.
2021-Present - Trunome partners with 6 major hospitals,
impacting over 1500 patients and expanding its reach.
2023 - Trunome and AcrannoLife continue to innovate in
healthcare, with plans for global expansion.
2024 - Agragesh aims to scale both companies, focusing on
personalized genomics and improving global healthcare access.
